MY150833A - Crystal of benzimidazole compound - Google Patents

Crystal of benzimidazole compound

Info

Publication number
MY150833A
MY150833A MYPI20104206A MY150833A MY 150833 A MY150833 A MY 150833A MY PI20104206 A MYPI20104206 A MY PI20104206A MY 150833 A MY150833 A MY 150833A
Authority
MY
Malaysia
Prior art keywords
crystal
benzimidazole compound
methyl
benzimidazole
trifluoroethoxy
Prior art date
Application number
Other languages
English (en)
Inventor
Hashimoto Hideo
Urai Tadashi
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40577894&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY150833(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of MY150833A publication Critical patent/MY150833A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
MYPI20104206 2008-03-10 2009-03-09 Crystal of benzimidazole compound MY150833A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2008059342 2008-03-10

Publications (1)

Publication Number Publication Date
MY150833A true MY150833A (en) 2014-02-28

Family

ID=40577894

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20104206 MY150833A (en) 2008-03-10 2009-03-09 Crystal of benzimidazole compound

Country Status (30)

Country Link
US (1) US8222422B2 (pt)
EP (1) EP2262790B1 (pt)
JP (3) JP2011513202A (pt)
KR (1) KR20100123758A (pt)
CN (1) CN102026994B (pt)
AR (1) AR070972A1 (pt)
AU (1) AU2009224247B2 (pt)
BR (1) BRPI0909651A2 (pt)
CA (1) CA2671369C (pt)
CL (1) CL2009000547A1 (pt)
CO (1) CO6300956A2 (pt)
CR (1) CR11707A (pt)
DO (1) DOP2010000274A (pt)
EA (1) EA017064B1 (pt)
EC (1) ECSP10010531A (pt)
ES (1) ES2638463T3 (pt)
GE (1) GEP20125649B (pt)
IL (1) IL207867A0 (pt)
LT (1) LT2262790T (pt)
MA (1) MA32215B1 (pt)
MX (1) MX2010009641A (pt)
MY (1) MY150833A (pt)
NZ (1) NZ588379A (pt)
PE (1) PE20091680A1 (pt)
PT (1) PT2262790T (pt)
TW (1) TWI447110B (pt)
UA (1) UA103189C2 (pt)
UY (1) UY31695A (pt)
WO (1) WO2009113696A1 (pt)
ZA (1) ZA201006754B (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011004387A2 (en) 2009-06-18 2011-01-13 Matrix Laboratories Ltd Process for the preparation of dexlansoprazole polymorphic forms
CN102108077B (zh) * 2009-12-23 2013-09-25 江苏豪森医药集团有限公司 制备右兰索拉唑的方法
WO2011092665A1 (en) * 2010-01-29 2011-08-04 Ranbaxy Laboratories Limited Process for the preparation of crystalline forms of dexlansoprazole
CN104447695A (zh) * 2013-11-22 2015-03-25 广东东阳光药业有限公司 一种苯并咪唑化合物的水合物
RU2672248C1 (ru) 2015-06-08 2018-11-13 СиДжей ХЕЛТКЕР КОРПОРЕЙШН Применение производного бензимидазола для лечения ночного кислотного прорыва
US11072614B2 (en) 2016-11-29 2021-07-27 Ptc Therapeutics Mp, Inc. Polymorphs of sepiapterin and salts thereof
EP3548487A4 (en) 2016-11-29 2020-04-29 Censa Pharmaceuticals Inc. POLYMORPHE SHAPE OF SEPIAPTERIN
CN106866631A (zh) * 2017-04-06 2017-06-20 山东裕欣药业有限公司 一种右旋兰索拉唑晶型及制备方法
CA3073957A1 (en) 2017-09-01 2019-03-07 Censa Pharmaceuticals Inc. Pharmaceutical compositions comprising sepiapterin and uses thereof
EP3801526B1 (en) 2018-05-25 2023-12-27 Imara Inc. Monohydrate and crystalline forms of 6-[(3s,4s)-4-methyl-1- (pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl- 7h-imid azo [1,5- a] pyrazin-8-one
WO2020013330A1 (ja) * 2018-07-13 2020-01-16 協和発酵バイオ株式会社 ユーコミン酸の非溶媒和物結晶及びその製造方法
CN113376273B (zh) * 2021-06-02 2023-03-17 国药集团精方（安徽）药业股份有限公司 一种清心莲子饮hplc特征图谱的检测方法及该特征图谱的应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6150978A (ja) 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
DK171989B1 (da) 1987-08-04 1997-09-08 Takeda Chemical Industries Ltd Fremgangsmåde til fremstilling af 2-(2-pyridylmethylsulfinyl)-benzimidazoler
DE4035455A1 (de) 1990-11-08 1992-05-14 Byk Gulden Lomberg Chem Fab Enantiomerentrennung
SE504459C2 (sv) 1994-07-15 1997-02-17 Astra Ab Förfarande för framställning av substituerade sulfoxider
GB9423968D0 (en) 1994-11-28 1995-01-11 Astra Ab Resolution
HRP960232A2 (en) 1995-07-03 1998-02-28 Astra Ab A process for the optical purification of compounds
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
TW385306B (en) * 1996-11-14 2000-03-21 Takeda Chemical Industries Ltd Method for producing crystals of benzimidazole derivatives
TR199901101T2 (xx) 1996-11-22 1999-07-21 The Procter & Gamble Company Gastroenstentinal hastal�klar�n tedavisine y�nelik bizmut ve nsaid i�eren bile�imler.
SE510666C2 (sv) 1996-12-20 1999-06-14 Astra Ab Nya Kristallmodifikationer
DK0987256T3 (da) * 1997-08-08 2002-02-11 Aventis Pharma Gmbh Krystalform af N-(4-trifluormethylphenyl)-5-methylisoxazol-4-carboxylsyreamid
AU742620B2 (en) 1998-01-30 2002-01-10 Sepracor, Inc. R-lansoprazole compositions and methods
AU2481899A (en) 1998-01-30 1999-08-16 Sepracor, Inc. S-lansoprazole compositions and methods
EP1075267A2 (en) 1998-05-06 2001-02-14 Kobenhavns Universitet Treatment of celiac disease
TWI289557B (en) 1999-06-17 2007-11-11 Takeda Chemical Industries Ltd A crystal of a hydrate of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
JP3283252B2 (ja) * 1999-06-17 2002-05-20 武田薬品工業株式会社 ベンズイミダゾール化合物の結晶
EP1293507B1 (en) 2000-05-15 2007-11-28 Takeda Pharmaceutical Company Limited Process for producing crystal
JP4327424B2 (ja) * 2000-05-15 2009-09-09 武田薬品工業株式会社 結晶の製造法
JP3374314B2 (ja) * 2000-05-15 2003-02-04 武田薬品工業株式会社 結晶の製造法
KR20100002278A (ko) * 2000-12-01 2010-01-06 다케다 야쿠힌 고교 가부시키가이샤 (ｒ)- 또는 (ｓ)-란소프라졸의 결정
JP4160293B2 (ja) * 2000-12-01 2008-10-01 武田薬品工業株式会社 結晶の製造法
EP1552833B1 (en) 2002-10-16 2016-12-28 Takeda Pharmaceutical Company Limited Process for producing an amorphous optically active isomer of lansoprazole
JP4749660B2 (ja) * 2002-10-16 2011-08-17 武田薬品工業株式会社 安定な固形製剤
EP2573082A1 (en) 2007-12-31 2013-03-27 Takeda Pharmaceutical Company Limited Crystalline solvated forms of (r)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1h-benzimidazole

Also Published As

Publication number Publication date
CA2671369C (en) 2011-05-10
CN102026994B (zh) 2014-05-07
IL207867A0 (en) 2010-12-30
LT2262790T (lt) 2017-08-25
JP2014015477A (ja) 2014-01-30
CL2009000547A1 (es) 2010-05-07
UA103189C2 (ru) 2013-09-25
AR070972A1 (es) 2010-05-19
GEP20125649B (en) 2012-09-25
WO2009113696A1 (en) 2009-09-17
EA017064B1 (ru) 2012-09-28
EP2262790B1 (en) 2017-06-07
TW200938531A (en) 2009-09-16
ZA201006754B (en) 2011-11-30
KR20100123758A (ko) 2010-11-24
TWI447110B (zh) 2014-08-01
AU2009224247A1 (en) 2009-09-17
DOP2010000274A (es) 2010-09-30
CA2671369A1 (en) 2009-09-10
AU2009224247A2 (en) 2010-10-28
PT2262790T (pt) 2017-07-18
BRPI0909651A2 (pt) 2015-09-22
JP2015163623A (ja) 2015-09-10
CR11707A (es) 2010-11-04
MX2010009641A (es) 2010-09-22
MA32215B1 (fr) 2011-04-01
NZ588379A (en) 2012-07-27
JP2011513202A (ja) 2011-04-28
EA201071053A1 (ru) 2011-04-29
EP2262790A1 (en) 2010-12-22
ES2638463T3 (es) 2017-10-20
UY31695A (es) 2009-11-10
PE20091680A1 (es) 2009-11-16
CN102026994A (zh) 2011-04-20
US8222422B2 (en) 2012-07-17
CO6300956A2 (es) 2011-07-21
US20110046183A1 (en) 2011-02-24
AU2009224247B2 (en) 2013-12-12
ECSP10010531A (es) 2010-11-30

Similar Documents

Publication Publication Date Title
UA103189C2 (ru) Кристаллическая форма бензимидазольного соединения
EP2292612A3 (en) Crystalline solvated forms of (r)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1h-benzimidazole
AR103295A2 (es) Compuesto cristalino de benzimidazol, composición farmacéutica que lo comprende y método para la manufactura de dicha composición
TNSN08089A1 (en) Substituted benzimidazoles and methods of preparation
ZA200810481B (en) Benzimidazole derivatives, method for the production thereof, their use as FXR agonists and pharmaceutical preparations containing the same
GEP20084341B (en) Aminoheteroaryl compounds as protein kinase inhibitors
WO2012001156A3 (en) Pharmaceutical oral dosage forms comprising dabigatran etexilate and its pharmaceutically acceptable salts
NO20084915L (no) Nikotinacetylcholinreseptorligander 101
EP2280955B8 (en) Crystalline form of 6-[(4s)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
MX2009006529A (es) Formas cristalinas de ilaprazol solvatado.
WO2008045777A3 (en) A process for the preparation of benzimidazole derivatives and their salts
NO20080033L (no) Kinolinderivater som NK3-antagonister
NO20034715L (no) Krystallinsk form av omeprazol
TN2009000068A1 (en) Salts of benzimidazolyl pyridyl ethers and formulations thereof
ZA989999B (en) New process for the preparation of 5-methoxy-2-(((4-methoxy-3,5-dimethyl-2-pyridinyl)methyl)sulfinyl)1H-benzimidazole
IL172266A0 (en) Process for preparing 2-[(pyridinyl)methyl]sulfinyl-substituted benzimidazoles and novel chlorinated derivatives of pantoprazole
WO2010095144A3 (en) Process for preparation of proton pump inhibitors
TN2010000400A1 (en) Crystal of benzimidazole compound
ZA200804492B (en) S-Omeprazole strontium or hydrate thereof, method for preparing same, and pharmaceutical composition comprising same
SE0302382D0 (sv) New salts II
WO2009066309A9 (en) Process for preparation of omeprazole
WO2008015530A3 (en) Stable solid oral formulation of pantoprazole
WO2007126826A3 (en) Synthesis and regioselective substitution of 6-halo- and 6-alkoxy nicotine derivatives
BRPI0515484A (pt) derivados piridìnicos de indolin-2-ona, o respectivo preparo e a respectiva aplicação em terapêutica
BR0015220A (pt) Procedimento melhorado para a preparação de derivados de benzimidazol adequados como fármacos antiulcerosos, principalmente omeprazol ou pantoprazol